18. Zydus Cadila

2014 Generics Sales: $1.2 billion +28%
Worldwide Market Share: 1.6%

Indian pharmaceutical company Zydus Cadila was able to break the $1 billion mark for generics sales last year, jumping to $1.2 billion in sales in 2014 from $900 million in 2013.

That 28% growth--one of the largest for the top 20 generics makers--enabled the unit to jump one position and land at 18. Its global market share went from 1.3% to 1.6%.

Zydus Cadila launched 9 new products in the U.S. during its 2014-2015 fiscal year, filing an additional 38 ANDAs with the FDA. In its annual report, company chairman Pankaj Patel said going forward, Zydus will "continue to focus on launching complex, difficult-to-make oral solids and formulations of other dosage forms like injectables, nasals, creams and ointments in order to enhance its share in the USA generics market."

In India, it launched more than 55 products, 19 of which were first-time launches, including adalimumab, the world's first biosimilar of $11 billion arthritis treatment Humira. Sales in India grew 8.6% on the year. And continuing its outward push, it looked to branding initiatives and strengthening branded generics in emerging markets, while launching 20 new products in different markets of Asia-Pacific, Africa and the Middle East.

As with many of its Indian peers, Cadila has spent a good portion of its time of late dealing with manufacturing woes, FDA actions and recalls. A July 2014 report that it had received an FDA Form 483 after an inspection at its Moraiya site took a bite out of its share price.

However, Cadila was able to grow its sales on the period, and in September 2014, it was involved in a high-profile move by Gilead ($GILD) to hand over its hep C drug Sovaldi's manufacturing tech to 7 drugmakers to bring cheap copies to 91 markets and about 100 million patients.

-- Eric Sagonowsky (email)

For more:
Gilead hands Sovaldi manufacturing tech to 7 generics makers
Report of Form 483 for Cadila wreaks havoc with its shares
India's IPA hires consulting firm to help it overcome bad publicity
Zydus recall flags another costly bottle mixup
Zydus Cadila bottling flop sparks another Indian recall

18. Zydus Cadila
Read more on

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.